BRISTOL-MYERS SQUIBB CO (BMY) Stock Fundamental Analysis
NYSE:BMY • US1101221083
60.74 USD
+0.88 (+1.47%)
At close: Feb 13, 2026
60.45 USD
-0.29 (-0.48%)
After Hours: 2/13/2026, 8:04:00 PM
Taking everything into account, BMY scores 6 out of 10 in our fundamental rating. BMY was compared to 191 industry peers in the Pharmaceuticals industry. BMY scores excellent on profitability, but there are some minor concerns on its financial health. BMY has a bad growth rate and is valued cheaply. Finally BMY also has an excellent dividend rating. These ratings could make BMY a good candidate for value and dividend investing.
1. Profitability
1.1 Basic Checks
- In the past year BMY was profitable.
- In the past year BMY had a positive cash flow from operations.
- BMY had positive earnings in 4 of the past 5 years.
- BMY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.23%, BMY belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 32.55%, BMY belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
- BMY has a Return On Invested Capital of 17.64%. This is amongst the best in the industry. BMY outperforms 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 17.64% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 12.57%, BMY belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
- In the last couple of years the Profit Margin of BMY has grown nicely.
- The Operating Margin of BMY (33.51%) is better than 95.29% of its industry peers.
- BMY's Operating Margin has improved in the last couple of years.
- BMY has a better Gross Margin (73.15%) than 80.63% of its industry peers.
- In the last couple of years the Gross Margin of BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMY is creating value.
- There is no outstanding debt for BMY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 2.33 indicates that BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of BMY (2.33) is better than 64.40% of its industry peers.
- The Debt to FCF ratio of BMY is 3.20, which is a good value as it means it would take BMY, 3.20 years of fcf income to pay off all of its debts.
- BMY's Debt to FCF ratio of 3.20 is amongst the best of the industry. BMY outperforms 88.48% of its industry peers.
- A Debt/Equity ratio of 2.41 is on the high side and indicates that BMY has dependencies on debt financing.
- The Debt to Equity ratio of BMY (2.41) is worse than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.33 |
ROIC/WACC2.04
WACC8.65%
2.3 Liquidity
- BMY has a Current Ratio of 1.27. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.27, BMY is doing worse than 77.49% of the companies in the same industry.
- BMY has a Quick Ratio of 1.17. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.17, BMY is not doing good in the industry: 75.39% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 439.47% over the past year.
- Measured over the past years, BMY shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
- BMY shows a decrease in Revenue. In the last year, the revenue decreased by -0.22%.
- The Revenue has been growing slightly by 2.54% on average over the past years.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- Based on estimates for the next years, BMY will show a decrease in Earnings Per Share. The EPS will decrease by -4.54% on average per year.
- BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.61% yearly.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 9.88, the valuation of BMY can be described as very reasonable.
- Based on the Price/Earnings ratio, BMY is valued cheaply inside the industry as 92.15% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.68. BMY is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 9.98, the valuation of BMY can be described as reasonable.
- Based on the Price/Forward Earnings ratio, BMY is valued cheaper than 88.48% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BMY to the average of the S&P500 Index (28.06), we can say BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.88 | ||
| Fwd PE | 9.98 |
4.2 Price Multiples
- 93.19% of the companies in the same industry are more expensive than BMY, based on the Enterprise Value to EBITDA ratio.
- BMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMY is cheaper than 93.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.08 | ||
| EV/EBITDA | 7.38 |
4.3 Compensation for Growth
- BMY has an outstanding profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BMY's earnings are expected to decrease with -3.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
5. Dividend
5.1 Amount
- BMY has a Yearly Dividend Yield of 4.21%, which is a nice return.
- BMY's Dividend Yield is rather good when compared to the industry average which is at 1.18. BMY pays more dividend than 96.86% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.84, BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
5.2 History
- On average, the dividend of BMY grows each year by 11.67%, which is quite nice.
- BMY has paid a dividend for at least 10 years, which is a reliable track record.
- BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- BMY pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
- BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
60.74
+0.88 (+1.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners81.87%
Inst Owner Change-90.74%
Ins Owners0.02%
Ins Owner Change-1.11%
Market Cap123.65B
Revenue(TTM)48.19B
Net Income(TTM)6.04B
Analysts70.59
Price Target58.05 (-4.43%)
Short Float %1.82%
Short Ratio2.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
Yearly Dividend2.42
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-Date01-02 2026-01-02 (0.63)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)5.02%
PT rev (3m)10.23%
EPS NQ rev (1m)-29.59%
EPS NQ rev (3m)-32.32%
EPS NY rev (1m)0.39%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.88 | ||
| Fwd PE | 9.98 | ||
| P/S | 2.57 | ||
| P/FCF | 8.08 | ||
| P/OCF | 7.44 | ||
| P/B | 6.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.38 |
EPS(TTM)6.15
EY10.13%
EPS(NY)6.09
Fwd EY10.02%
FCF(TTM)7.52
FCFY12.38%
OCF(TTM)8.16
OCFY13.44%
SpS23.6
BVpS9.11
TBVpS-11.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 17.64% | ||
| ROICexc | 23.19% | ||
| ROICexgc | 118.19% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.33 |
F-Score6
WACC8.65%
ROIC/WACC2.04
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
EBIT growth 1Y44.7%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y10.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.78%
OCF growth 3YN/A
OCF growth 5YN/A
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BMY.
What is the valuation status for BMY stock?
ChartMill assigns a valuation rating of 8 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.
What is the profitability of BMY stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 8 / 10.
Can you provide the financial health for BMY stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BMY) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BMY) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to decline by -1.05% in the next year.